Access

Letters to Nature

Nature 431, 461-466 (1 September 2004) | doi:10.1038/nature02924; Received 14 June 2004; Accepted 10 August 2004; Published online 25 August 2004

Open Innovation Challenges

  • Optimizing Sub-cellular Localization Tags

    • Deadline: Nov 29 2009
    • Reward: $20,000 USD

    The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....

  • Single-cell Analysis Platform

    • Deadline: Dec 02 2009
    • Reward: $5,000 USD

    This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

Eli Pikarsky1,5, Rinnat M. Porat1,5, Ilan Stein1,2,5, Rinat Abramovitch3, Sharon Amit2, Shafika Kasem1, Elena Gutkovich-Pyest2, Simcha Urieli-Shoval4, Eithan Galun3 & Yinon Ben-Neriah2

  1. Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
  2. The Lautenberg Center for Immunology, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel
  3. Goldyne Savad Institute of Gene Therapy, Jerusalem 91120, Israel
  4. Hematology Unit, Hadassah University Hospital, Mount Scopus, Jerusalem 91120, Israel
  5. These authors contributed equally to this work

Correspondence to: Eli Pikarsky1,5Yinon Ben-Neriah2 Email: peli@hadassah.org.il
Email: yinon@cc.huji.ac.il

Top

The causes of sporadic human cancer are seldom recognized, but it is estimated that carcinogen exposure and chronic inflammation are two important underlying conditions for tumour development, the latter accounting for approximately 20% of human cancer1. Whereas the causal relationship between carcinogen exposure and cancer has been intensely investigated2, the molecular and cellular mechanisms linking chronic inflammation to tumorigenesis remain largely unresolved1. We proposed that activation of the nuclear factor kappaB (NF-kappaB), a hallmark of inflammatory responses3 that is frequently detected in tumours4, 5, may constitute a missing link between inflammation and cancer. To test this hypothesis, we studied the Mdr2-knockout mouse strain, which spontaneously develops cholestatic hepatitis followed by hepatocellular carcinoma6, a prototype of inflammation-associated cancer7. We monitored hepatitis and cancer progression in Mdr2-knockout mice, and here we show that the inflammatory process triggers hepatocyte NF-kappaB through upregulation of tumour-necrosis factor-alpha (TNFalpha) in adjacent endothelial and inflammatory cells. Switching off NF-kappaB in mice from birth to seven months of age, using a hepatocyte-specific inducible IkappaB-super-repressor transgene, had no effect on the course of hepatitis, nor did it affect early phases of hepatocyte transformation. By contrast, suppressing NF-kappaB inhibition through anti-TNFalpha treatment or induction of IkappaB-super-repressor in later stages of tumour development resulted in apoptosis of transformed hepatocytes and failure to progress to hepatocellular carcinoma. Our studies thus indicate that NF-kappaB is essential for promoting inflammation-associated cancer, and is therefore a potential target for cancer prevention in chronic inflammatory diseases.

  1. Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
  2. The Lautenberg Center for Immunology, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel
  3. Goldyne Savad Institute of Gene Therapy, Jerusalem 91120, Israel
  4. Hematology Unit, Hadassah University Hospital, Mount Scopus, Jerusalem 91120, Israel
  5. These authors contributed equally to this work

Correspondence to: Eli Pikarsky1,5Yinon Ben-Neriah2 Email: peli@hadassah.org.il
Email: yinon@cc.huji.ac.il

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.